All In Biotech

Free tool

FAERS Monitor: Imkeldi

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 219097 or its brand name (Imkeldi, Imatinib Mesylate). Reports on generic versions are filed under their own applications.

Reports

9

Serious

9

100% of reports

Hospitalization

8

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • hospitalisation3
  • pneumonia2
  • therapy interrupted2
  • blister1
  • blood bilirubin increased1
  • cardiogenic shock1
  • catheterisation cardiac1
  • dependence on respirator1
  • dysphagia1
  • dyspnoea1
  • electrolyte imbalance1
  • erythema1
  • febrile neutropenia1
  • fluid retention1
  • hyponatraemia1

Reports by year received

View as table
YearReports
20231
20252
20266

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,150 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
dependence on respirator15848.4919.11,457
catheterisation cardiac1527.283.1131
electrolyte imbalance1201.231.749
cardiogenic shock1162.925.740
blood bilirubin increased186.513.621
therapy interrupted265.419.371
fluid retention146.07.211
hospitalisationSignal345.618.191
blister141.66.69
hyponatraemia141.56.59
febrile neutropenia135.25.68
dysphagia124.63.95
pneumonia214.44.314
erythema111.41.82
dyspnoea14.10.70

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.